Mirabet 25mg treats overactive bladder (OAB) — a condition causing sudden urge to urinate, frequent urination, and urinary incontinence. Each tablet contains mirabegron 25mg, the initiation dose for this selective beta-3 adrenergic receptor agonist. Buy Mirabet 25mg online at PakMeds and save on genuine, prescription verified medicine delivered to your door.

Mirabet 25mg Ingredients and Usage

Mirabet 25mg contains mirabegron — a selective beta-3 adrenergic receptor (β3-AR) agonist and the first drug in its class approved by the FDA for overactive bladder. It treats the three core OAB symptoms: urinary urgency, urge urinary incontinence, and increased urinary frequency. Mirabet is also used in combination with the muscarinic antagonist solifenacin for patients who need stronger OAB control.

Mirabet 25mg is the recommended starting dose for all adult OAB patients. It is also the maximum permitted dose for patients with severe renal impairment (eGFR 15–29 mL/min) or moderate hepatic impairment (Child-Pugh B). After 4 to 8 weeks at 25mg, the prescriber may escalate to 50mg if the patient tolerates treatment and needs greater symptom control.

How Does Mirabet 25mg Work?

Mirabet 25mg works by selectively activating beta-3 adrenergic receptors (β3-ARs) in the detrusor — the smooth muscle layer of the bladder wall. β3-AR stimulation triggers a cyclic AMP mediated signalling cascade that causes the detrusor to relax during the bladder-filling phase. This relaxation directly increases the volume of urine the bladder can hold before triggering the urge to void.

Unlike antimuscarinic OAB drugs, mirabegron does not block muscarinic receptors in the salivary glands or bowel. This means Mirabet produces up to six times less dry mouth than antimuscarinics, confirmed in comparative clinical trials. It also avoids the cognitive and constipation side effects commonly seen with older OAB medicines.

Mirabet 25mg Side Effects

Mirabet 25mg is generally well tolerated. In three 12-week placebo-controlled FDA registration trials involving 2,736 OAB patients, the most commonly reported adverse effects were:

• Hypertension — reported in 11.3% of patients on 25mg versus 7.6% on placebo; monitor blood pressure regularly
• Urinary tract infection (UTI) — reported in 4.2% of patients; report symptoms of burning or pain on urination promptly
• Nasopharyngitis — reported in 3.5% of patients; common cold-like upper respiratory symptoms
• Headache — reported in 2.1% of patients during the treatment period
• Tachycardia and palpitations — elevated heart rate, more common at higher doses
• Back pain and joint pain — musculoskeletal effects reported post-marketing
• Dizziness, nausea, and diarrhea — reported in post-marketing surveillance
• Confusion, insomnia, or anxiety — rare post-marketing reports; inform your doctor if these occur

Warnings

• Severe uncontrolled hypertension — contraindicated: Do not use Mirabet in patients with systolic blood pressure ≥180 mmHg and/or diastolic blood pressure ≥110 mmHg. Monitor blood pressure periodically during treatment, especially in patients with pre-existing hypertension.
• Hypersensitivity — contraindicated: Mirabet is contraindicated in patients with a known allergic reaction to mirabegron or any tablet excipient. Discontinue immediately if a reaction occurs.
• Angioedema: Post-marketing reports document angioedema of the face, lips, tongue, and larynx. This can be life-threatening. Discontinue Mirabet immediately and seek emergency care if swelling develops.
• Urinary retention: Mirabet can cause urinary retention in patients with bladder outlet obstruction. Use with caution in patients with clinically significant bladder outlet obstruction or benign prostatic hyperplasia. Risk increases when combined with antimuscarinic OAB drugs.
• CYP2D6 drug interactions: Mirabegron is a moderate CYP2D6 inhibitor. It raises plasma levels of CYP2D6 substrates including metoprolol, desipramine, thioridazine, flecainide, and propafenone. Dose adjustment and monitoring are required for narrow therapeutic index CYP2D6 drugs.
• Digoxin interaction: Start with the lowest available digoxin dose when initiating Mirabet. Monitor serum digoxin concentrations regularly and titrate to clinical effect.
• CYP3A4 inhibitors: Strong CYP3A4 inhibitors such as ketoconazole increase mirabegron plasma exposure by up to 80%. Use with caution and consider dose reduction if concurrent use is unavoidable.
• Severe renal impairment (eGFR 15–29 mL/min): Do not exceed 25mg per day. Mirabet is not recommended in patients with end-stage renal disease (eGFR below 15 mL/min) or on dialysis.
• Moderate hepatic impairment (Child-Pugh B): Do not exceed 25mg per day. Mirabet is contraindicated in severe hepatic impairment (Child-Pugh C).
• Pregnancy: Insufficient safety data exist for use during pregnancy. Use only if the potential benefit justifies the risk to the fetus. Consult your doctor before starting treatment.
• Breastfeeding: Mirabegron is found in the milk of lactating animals. Human data are insufficient. Discuss the risks and benefits with your doctor before breastfeeding while on Mirabet.

Mirabet 25mg Storage Conditions

• Store below 30°C at room temperature
• Protect from direct heat, sunlight, and moisture at all times
• Keep in the original packaging until use
• Do not store in the bathroom — humidity degrades the tablets
• Keep out of reach of children at all times
• Dispose of expired or unused tablets as directed by your pharmacist — do not flush or discard in household waste

Mirabet 25mg Price in Pakistan

Mirabet 25mg is available in Pakistan at approximately Rs. 724 to Rs. 804 per pack of 20 tablets (Healthwire). Prices vary across pharmacies and availability. Mirabet is a specialist urology medicine with limited generic competition in Pakistan at this time.

PakMeds stocks genuine CCL Pharmaceuticals Mirabet 25mg with fast, verified delivery nationwide. Order Mirabet 25mg at PakMeds today and save on your OAB prescription without compromising on authenticity.

Mirabet 25mg — Frequently Asked Questions

How long does Mirabet 25mg take to work?

Mirabet 25mg reaches peak plasma concentration within approximately one hour of oral administration. However, full symptom improvement in overactive bladder typically takes 4 to 8 weeks of consistent once daily dosing. Most patients notice a gradual reduction in urgency episodes and toilet visits within the first month.

Clinical trials showed statistically significant reductions in urgency incontinence episodes, micturition frequency, and urgency severity at both 4 and 12 weeks. Continue taking Mirabet as prescribed even if early improvement seems modest. Your urologist will reassess at 4 to 8 weeks to confirm whether a dose increase to 50mg is warranted.

Why is 25mg the starting dose for Mirabet?

Mirabet 25mg is the recommended initiation dose because it allows the body to adjust to mirabegron’s effects — particularly its mild blood pressure-elevating action. Starting at 25mg reduces the risk of early hypertension and cardiovascular side effects before full tolerability is established. Clinical guidelines and the FDA prescribing information both specify 25mg as the appropriate dose for treatment initiation.

For patients with severe renal impairment or moderate liver disease, 25mg is also the permanent maximum dose — escalation to 50mg is not safe in these groups. All other eligible adults may step up to 50mg after 4 to 8 weeks if the 25mg dose does not deliver sufficient OAB symptom control. Never self-adjust the dose without medical guidance.

Is Mirabet 25mg better than antimuscarinic OAB medicines?

Mirabet (mirabegron) works through a fundamentally different mechanism than antimuscarinics like oxybutynin, tolterodine, and solifenacin. Antimuscarinics block muscarinic receptors across multiple organs, causing dry mouth, constipation, blurred vision, and cognitive effects. Mirabet selectively targets beta-3 receptors in the bladder, producing up to six times less dry mouth than antimuscarinics in comparative trials.

Mirabet is particularly preferred for elderly patients where anticholinergic burden from antimuscarinics poses a higher risk of falls and cognitive decline. It can also be combined with solifenacin for patients who need a dual mechanism approach. Your urologist will determine which therapy, or combination, best matches your OAB severity and overall health profile.